Eprobe-mediated screening system for somatic mutations in the KRAS locus

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations predict resistance to epidermal growth factor receptor (EGFR) therapy in colorectal cancer (CRC).
• Current methods for detecting KRAS mutations lack sensitivity, feasibility, and cost-effectiveness.
• A need exists for a highly sensitive and user-friendly KRAS mutation detection system for clinical applications.

Purpose of the Study:

• To develop and validate a novel fluorescence Eprobe-based real-time PCR system for sensitive detection of KRAS gene mutations.
• To assess the sensitivity and usability of the Eprobe system compared to conventional methods.

Main Methods:

• Development of fluorescence Eprobes complementary to wild-type (WT) KRAS and common KRAS mutations (codons 12 and 13).
• Utilizing Eprobe-PCR to detect low-level KRAS mutations by suppressing WT amplification and enriching mutant amplicons.
• Comparative analysis of Eprobe-PCR with Sanger sequencing and next-generation sequencing (NGS) in 92 CRC patient samples.

Main Results:

• The Eprobe system demonstrated high sensitivity in detecting KRAS mutations (0.05-0.1% plasmid DNA, 1% genomic DNA).
• Eprobe-PCR identified KRAS mutations in CRC samples that were undetectable by Sanger sequencing.
• The Eprobe system exhibited higher sensitivity than Sanger sequencing for KRAS mutation detection in patient samples.

Conclusions:

• The novel Eprobe-PCR system provides a highly sensitive, user-friendly, and cost-effective method for detecting KRAS mutations.
• This technology holds significant potential for improving diagnostic accuracy and guiding therapeutic decisions in colorectal cancer treatment.
• The Eprobe approach is a valuable tool for clinical diagnostics, particularly for identifying low-level KRAS mutations.